David Hebrank
Vice President, Business Development
Retia Medical develops and sells advanced algorithms and monitors for guiding care for high-risk surgical and critically ill patients. The Argos Cardiac Output Monitor provides consistent accuracy using Multi-Beat Analysis(TM), rapid setup, and an intuitive user interface while avoiding costly proprietary disposables. Approximately 20 million surgical intensive care patients worldwide could benefit from this technology.
Based in White Plains, NY, Retia’s technology was developed at Michigan State University and Massachusetts Institute of Technology and validated through extensive tests in animals and humans. With the support of a strong advisory board comprised of industry and clinical experts, Retia received FDA 510(k) clearance and launched this product in December 2018, which will help revolutionize the care of the most at-risk patients.
Based in White Plains, NY, Retia’s technology was developed at Michigan State University and Massachusetts Institute of Technology and validated through extensive tests in animals and humans. With the support of a strong advisory board comprised of industry and clinical experts, Retia received FDA 510(k) clearance and launched this product in December 2018, which will help revolutionize the care of the most at-risk patients.
